Cited by 278Liver Disease Diagnosis and TreatmentLiver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation

Open access

Ibrahim, Samar H, Hirsova, Petra, Gores, Gregory J·2018·Gut

DOI 10.1136/gutjnl-2017-315691PMC PMC5889737

Open this paper in CoChat — free account

Abstract

A subset of patients with non-alcoholic fatty liver disease develop an inflammatory condition, termed non-alcoholic steatohepatitis (NASH). NASH is characterised by hepatocellular injury, innate immune cell-mediated inflammation and progressive liver fibrosis. The mechanisms whereby hepatic inflammation occurs in NASH remain incompletely understood, but appear to be linked to the proinflammatory microenvironment created by toxic lipid-induced hepatocyte injury, termed lipotoxicity. In this review, we discuss the signalling pathways induced by sublethal hepatocyte lipid overload that contribute to the pathogenesis of NASH. Furthermore, we will review the role of proinflammatory, proangiogenic and profibrotic hepatocyte-derived extracellular vesicles as disease biomarkers and pathogenic mediators during lipotoxicity. We also review the potential therapeutic strategies to block the feed-forward loop between sublethal hepatocyte injury and liver inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-315691

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915
Extracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,466
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295

Show all 89 references

Research works printed but not linked: 1

Lefebvre, 2013, Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH, Hepatology, 58, 221

Sorted by citations

Items 101–200 of 278

Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis
García‐Martinez, I., Alén, R., Rada, P., & Valverde, Á. M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00395 · Cited by 32
Biglycan: A regulator of hepatorenal inflammation and autophagy
McCoy, M. S., Diehl, V., Trebicka, J., Wygrecka, M., & Schaefer, L. (2021) · Matrix Biology · doi:10.1016/j.matbio.2021.06.001 · Cited by 32
Isolation and Culture of Mouse Hepatocytes and Kupffer Cells (KCs)
Mendoza, R. G., Banerjee, I., Reghupaty, S. C., Rajesh, Y., Manna, D., & Sarkar, D. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2128-8_7 · Cited by 39
Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11
Katsumi, T., Guicciardi, M. E., Azad, A. I., Bronk, S. F., Krishnan, A., & Gores, G. J. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00250.2019 · Cited by 32
Self-citation
Sinusoidal endotheliopathy in nonalcoholic steatohepatitis: therapeutic implications
Ibrahim, S. H. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00009.2021 · Cited by 31
Self-citation
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
Valenti, L., Pedica, F., & Colombo, M. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.06.023 · Cited by 25
Lipotoxic hepatocytes promote nonalcoholic fatty liver disease progression by delivering microRNA-9-5p and activating macrophages
Liu, H., Niu, Q., Wang, T., Dong, H., & Bian, C. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.57610 · Cited by 32
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 34
Lipotoxic stress alters the membrane lipid profile of extracellular vesicles released by Huh-7 hepatocarcinoma cells
Buratta, S., Shimanaka, Y., Costanzi, E., Ni, S., Urbanelli, L., Kono, N., Morena, F., Sagini, K., Giovagnoli, S., Romani, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84268-9 · Cited by 30
Hepatic lymphocytes involved in the pathogenesis of pediatric and adult non-alcoholic fatty liver disease
Cairoli, V., Matteo, E. D., Rios, D. A., Lezama, C., Galoppo, M., Casciato, P. C., Müllen, E., Giadans, C. G., Bertot, G. M., Preciado, M. V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84674-z · Cited by 31
Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis
Hirsova, P., Böhm, F., Dohnalkova, E., Nožičková, B., Heikenwalder, M., Gores, G., & Weber, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2283-9 · Cited by 27
Self-citation
Total liver phosphatidylcholine content associates with non‐alcoholic steatohepatitis and glycine N‐methyltransferase expression
Männistö, V., Kamińska, D., Kärjä, V. J., Tiainen, M., de Mello, V. D., Hanhineva, K., Soininen, P., Ala‐Korpela, M., & Pihlajamäki, J. (2019) · Liver International · doi:10.1111/liv.14174 · Cited by 29
Aloin protects mice from diet-induced non-alcoholic steatohepatitis via activation of Nrf2/HO-1 signaling
Xu, Q., Fan, Y., Loor, J. J., Liang, Y., Lv, H., Sun, X., Jia, H., & Xu, C. (2020) · Food & Function · doi:10.1039/d0fo02684k · Cited by 28
Ubiquitination of cytoplasmic HMGB1 by RNF186 regulates hepatic lipophagy in non-alcoholic fatty liver disease
Du, J., Ji, X. L., Xu, B., Du, Q., Li, Y., Zhou, B., Liu, X., Xu, Z., Jiang, Y. J., Kou, B., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155769 · Cited by 27
Retinol from hepatic stellate cells via STRA6 induces lipogenesis on hepatocytes during fibrosis
Hwang, I., Lee, E. J., Park, H., Moon, D., & Kim, H.-S. (2021) · Cell & Bioscience · doi:10.1186/s13578-020-00509-w · Cited by 28
Environmental toxicant-induced maladaptive mitochondrial changes: A potential unifying mechanism in fatty liver disease?
Schnegelberger, R. D., Lang, A. L., Arteel, G. E., & Beier, J. I. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.002 · Cited by 27
Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
Banerjee, T., Sarkar, A., Ali, S. Z., Bhowmik, R., Karmakar, S., Halder, A. K., & Ghosh, N. (2024) · Planta Medica · doi:10.1055/a-2277-4805 · Cited by 26
Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding
Yu, Q., & Song, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431652 · Cited by 27
Molecular Pathways Modulated by Mesenchymal Stromal Cells and Their Extracellular Vesicles in Experimental Models of Liver Fibrosis
Chiabotto, G., Pasquino, C., Camussi, G., & Bruno, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.594794 · Cited by 28
Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review
Chen, Y., Wu, W., & Wu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175999 · Cited by 29
A Comparative Proteomic Analysis of Extracellular Vesicles Associated With Lipotoxicity
Nakao, Y., Fukushima, M., Mauer, A. S., Liao, C., Ferris, A., Dasgupta, D., Heppelmann, C. J. H., Vanderboom, P. M., Saraswat, M., Pandey, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.735001 · Cited by 26
Scavenger Receptors: Novel Roles in the Pathogenesis of Liver Inflammation and Cancer
Patten, D. A., Wilkinson, A. L., O'Keeffe, A., & Shetty, S. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1733876 · Cited by 26
RIP kinases and necroptosis in aging and aging-related diseases
Yang, Y., Li, X., Zhang, T., & Xu, D. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac003 · Cited by 27
Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
Yu, P., Xu, X., Zhang, J., Xia, X., Xu, F. L., Weng, J., Lai, X., & Shen, Y. (2019) · International Journal of Endocrinology · doi:10.1155/2019/1567095 · Cited by 24
Leukocyte cell‐derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT‐1 pathway in mice
Wang, J., Chen, Y., Pan, R., Wu, C., Chen, S., Li, L., Li, Y., Yu, C., Meng, Z., & Xu, C. (2021) · Liver International · doi:10.1111/liv.14816 · Cited by 23
Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF‐κB pathway
Tu, S., Jiang, Y., Cheng, H., Yuan, X., He, Y. Z., Peng, Y., Peng, X., Peng, Z., Tao, L., & Yang, H. (2021) · The FASEB Journal · doi:10.1096/fj.202002402r · Cited by 22
Schizandrin C regulates lipid metabolism and inflammation in liver fibrosis by NF-κB and p38/ERK MAPK signaling pathways
Chen, P., Wang, R., Liu, F., Li, S., Gu, Y., Wang, L., & Yuan, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1092151 · Cited by 23
Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact
Ipsen, D. H., & Tveden‐Nyborg, P. (2021) · Biomedicines · doi:10.3390/biomedicines9010093 · Cited by 22
Osteocalcin Alleviates Nonalcoholic Fatty Liver Disease in Mice through GPRC6A
Zhang, M., Nie, X., Yuan, Y., Wang, Y., Ma, X., Yin, J., & Bao, Y. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9178616 · Cited by 22
Natural-Product-Mediated Autophagy in the Treatment of Various Liver Diseases
Fan, G., Li, F., Wang, P., Jin, X., & Liu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315109 · Cited by 22
Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
Han, D., Xu, K., Jin, Z., Xu, Y., Li, Y., Wang, L., Cao, Q., Kim, K.-P., Ryu, D. H., Hong, K., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85145 · Cited by 21
The Role of Stabilin-1 in Lymphocyte Trafficking and Macrophage Scavenging in the Liver Microenvironment
Patten, D. A., & Shetty, S. (2019) · Biomolecules · doi:10.3390/biom9070283 · Cited by 23
Aquaporin 9 Represents a Novel Target of Chronic Liver Injury That May Antagonize Its Progression by Reducing Lipotoxicity
Cheng, Q., Ding, H., Fang, J., Fang, X., Liu, H., Wang, J., Chen, C., & Zhang, W. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5653700 · Cited by 20
Attenuating effects of allantoin on oxidative stress in a mouse model of nonalcoholic steatohepatitis
Hamidizad, Z., Moslehi, A., & Rastegarpanah, M. (2021) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.327511 · Cited by 20
Phosphodiesterase 4 inhibitors in diabetic nephropathy
Ookawara, M., & Nio, Y. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110185 · Cited by 20
Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population
Gao, H. Y., Liu, S., Zhao, Z., Yu, X., Liu, Q., Xin, Y., & Xuan, S. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00030 · Cited by 19
Target-Engineered Liposomes Decorated with Nanozymes Alleviate Liver Fibrosis by Remodeling the Liver Microenvironment
Yang, D., Liu, K., Cai, C., Xi, J., Yan, C., Peng, Z., Wang, Y., Jing, L., Zhang, Y., Xie, F., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c14357 · Cited by 21
Role of extracellular vesicles in nonalcoholic fatty liver disease
Jiang, W., Xu, Y., Chen, J.-C., Lee, Y.-H., Hu, Y., Liu, C., Chen, E., Tang, H., Zhang, H., & Wu, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1196831 · Cited by 20
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
Tucker, R. D., Ciofoaia, V., Nadella, S., Gay, M. D., Cao, H., Huber, M., Safronenka, A., Shivapurkar, N., Kallakury, B., Kruger, A. J., et al. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05722-3 · Cited by 19
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways
Paquette, M., Yan, M., Ramírez-Reyes, J. M. J., El–Houjeiri, L., Biondini, M., Dufour, C. R., Jeong, H., Pacis, A., Giguère, V., Estall, J. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99958-7 · Cited by 17
Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of non-alcoholic steatohepatitis in mice
Kawashita, E., Ozaki, T., Ishihara, K., Kashiwada, C., & Akiba, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120355 · Cited by 18
Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
Zhang, F., Han, Y., Wu, Y., Bao, Z., Zheng, G., Liu, J., & Li, W. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2409342 · Cited by 20
Exosomal FZD-7 Expression Is Modulated by Different Lifestyle Interventions in Patients with NAFLD
Scavo, M. P., Depalo, N., Rizzi, F. R., Carrieri, L., Serino, G., Franco, I., Bonfiglio, C., Pesole, P. L., Cozzolongo, R., Giannuzzi, V., et al. (2022) · Nutrients · doi:10.3390/nu14061133 · Cited by 18
SHP‐1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production
Lin, L., Jian, J., Song, C., Chen, F., Ding, K., Xie, W., & Hu, P. (2020) · FEBS Letters · doi:10.1002/1873-3468.13879 · Cited by 17
Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity
Zhihong, Y., Chen, W., Qianqian, Z., Lidan, S., Zhou, Q., Han, J. D. J., Wenxi, W., & Bhawal, R. P. (2023) · Peptides · doi:10.1016/j.peptides.2023.170955 · Cited by 17
Marine algal polysaccharides as future potential constituents against non-alcoholic steatohepatitis
Lu, S., Tan, K., Zhong, S., & Cheong, K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126247 · Cited by 17
The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1
Li, Y., Chen, L., Sottas, C. M., Raul, M. C., Patel, N. D., Bijja, J. R., Ahmed, S. K., Kapelanski‐Lamoureux, A., Lazaris, A., Metrakos, P. P., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155942 · Cited by 18
Amplifying hepatic L-aspartate levels suppresses CCl4-induced liver fibrosis by reversing glucocorticoid receptor β-mediated mitochondrial malfunction
Su, R. J., Fu, H., Zhang, Q.-X., Wu, C., Yang, G.-Y., Wu, J.-J., Cao, W., Liu, J., Jiang, Z., Xu, C., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107294 · Cited by 17
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yang, Y., Zhao, Y., Li, W., Wu, Y., Wang, X., Wang, Y., Liu, T.-M., Ye, T., Xie, Y., Cheng, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112311 · Cited by 17
Membrane Remodeling as a Key Player of the Hepatotoxicity Induced by Co-Exposure to Benzo[a]pyrene and Ethanol of Obese Zebrafish Larvae
Imran, M., Sergent, O., Tête, A., Gallais, I., Chevanne, M., Lagadic‐Gossmann, D., & Podechard, N. (2018) · Biomolecules · doi:10.3390/biom8020026 · Cited by 17
Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver
Hu, M., & Huang, L. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201805760 · Cited by 17
MIF-mediated crosstalk between THRSP+ hepatocytes and CD74+ lipid-associated macrophages in hepatic periportal zone drives MASH
Xu, X., Li, H., Lin, H., Li, Q., Liu, Y., Huang, W., Yang, J., Li, N., Gao, Z., Wang, S., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001429 · Cited by 16
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Ádori, M., Bhat, S. H., Gramignoli, R., Valladolid‐Acebes, I., Bengtsson, T., Uhlén, M., & Ádori, C. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-57237 · Cited by 20
Pathological Microenvironment‐Remodeling Nanoparticles to Alleviate Liver Fibrosis: Reversing Hepatocytes‐Hepatic Stellate Cells Malignant Crosstalk
Zhang, L., Deng, W., Wang, X., Huang, Q., Liang, S., Ding, Z., Qi, L., Wang, Y., Zhou, T., Xing, L., et al. (2024) · Advanced Science · doi:10.1002/advs.202408898 · Cited by 15
Hepatoprotective Effect and Molecular Mechanisms of Hengshun Aromatic Vinegar on Non-Alcoholic Fatty Liver Disease
Zhu, S., Guan, L., Tan, X., Li, G., Sun, C., Gao, M., Zhang, B., & Xu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585582 · Cited by 15
Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression
Sakai, N., Kamimura, K., Miyamoto, H., Ko, M., Nagoya, T., Setsu, T., Sakamaki, A., Yokoo, T., Kamimura, H., Soki, H., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01929-w · Cited by 15
A1AT dysregulation of metabolically stressed hepatocytes by Kupffer cells drives MASH and fibrosis
Park, J.-S., Lee, J., Wang, F., Ma, H., Zhou, Z., Lee, Y.-S., Oh, K., Lee, H., Sui, G., Lee, S., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01408-1 · Cited by 15
The role of liver sinusoidal endothelial cells in metabolic dysfunction-associated steatotic liver diseases and liver cancer: mechanisms and potential therapies
Mo, H., Yue, P., Li, Q., Tan, Y., Yan, X., Liu, X., Xu, Y., Luo, Y., Palihati, S., Yi, C., et al. (2025) · Angiogenesis · doi:10.1007/s10456-025-09969-5 · Cited by 15
Bioinformatics analysis and machine learning approach applied to the identification of novel key genes involved in non-alcoholic fatty liver disease
Nazari, E., Khalili‐Tanha, G., Asadnia, A., Pourali, G., Maftooh, M., Khazaei, M., Nasiri, M., Hassanian, S. M., Ghayour‐Mobarhan, M., Ferns, G. A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46711-x · Cited by 14
Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis
Zhu, B., Wu, H., Li, K. S., Eisa-Beygi, S., Singh, B., Bielenberg, D. R., Huang, W., & Chen, H. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107249 · Cited by 14
Hepatic‐specific Pgc‐1α ablation drives fibrosis in a MASH model
Arconzo, M., Piccinin, E., Pasculli, E., Cariello, M., Loiseau, N., Bertrand‐Michel, J., Guillou, H., Matrella, M. L., Villani, G., & Moschetta, A. (2024) · Liver International · doi:10.1111/liv.16052 · Cited by 14
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway
Liu, Z., Wei, S., Jiang, Y. Z., Su, W., Ma, F., Cai, G., Liu, Y., Sun, X., Lu, L., Fu, W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.003 · Cited by 15
Allantoin improves methionine-choline deficient diet-induced nonalcoholic steatohepatitis in mice through involvement in endoplasmic reticulum stress and hepatocytes apoptosis-related genes expressions.
Movahhed, T. K., Moslehi, A., Golchoob, M., & Ababzadeh, S. (2019) · PubMed Central · doi:10.22038/ijbms.2019.33553.8012 · Cited by 14
Liver-derived extracellular vesicles: A cell by cell overview to isolation and characterization practices
Zivko, C., Fuhrmann, G., & Luciani, P. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129559 · Cited by 13
Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
Igreja, I. C., Tripská, K., Hroch, M., Hyšpler, R., Tichá, A., Laštůvková, H., Schreiberová, J., Doleželová, E., Eissazadeh, S., Vitverová, B., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239021 · Cited by 14
Is Fasting Good When One Is at Risk of Liver Cancer?
Minciună, I., van Kleef, L. A., Ştefănescu, H., & Procopeț, B. (2022) · Cancers · doi:10.3390/cancers14205084 · Cited by 13
Nonalcoholic Steatohepatitis Promoting Kinases
Ibrahim, S. H., Hirsova, P., Malhi, H., & Gores, G. J. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1713115 · Cited by 13
Self-citation
Playing Jekyll and Hyde—The Dual Role of Lipids in Fatty Liver Disease
Molenaar, M. R., Penning, L. C., & Helms, J. B. (2020) · Cells · doi:10.3390/cells9102244 · Cited by 12
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis
Luci, C., Vieira, E., Bourinet, M., Rousseau, D., Bonnafous, S., Patouraux, S., Lefevre, L., Larbret, F., Prod’homme, V., Iannelli, A., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.08.004 · Cited by 14
Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr−/−.Leiden mice
Gart, E., van Duyvenvoorde, W., Snabel, J. M., de Ruiter, C., Attema, J., Caspers, M. P. M., Lek, S., van Heuven, B. J., Speksnijder, A. G. C. L., Giera, M. A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13985 · Cited by 13
Marginal iron deficiency enhances liver triglyceride accumulation in rats fed a high-sucrose diet
Hori, S., Hara, H., & Ishizuka, S. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1515616 · Cited by 14
The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers
Wang, Q., Tang, X., Wang, Y., Zhang, D.-Y., Li, X., & Liu, S. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.009 · Cited by 12
Docosahexaenoic Acid Attenuates the Progression of Nonalcoholic Steatohepatitis by Suppressing the Adipocyte Inflammation via the G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 Pathway
Nakamoto, K., & Tokuyama, S. (2022) · Pharmacology · doi:10.1159/000522117 · Cited by 12
Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Kim, K., & Kim, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072296 · Cited by 13
YAP contributes to liver injury through mediating capillarization of liver sinusoidal endothelial cells via GATA6/eNOS signaling
Wang, J., Shen, Z., Chen, G., Dai, W., Mei, Z., Shen, B., Guo, Y., Wang, J., Zhangdi, H., Zhang, Q., et al. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00798-4 · Cited by 12
Relationship between MASLD and women’s health: A review
Jančová, P., Ismail, K. M., & Vištějnová, L. (2025) · Women s Health · doi:10.1177/17455057251376883 · Cited by 13
Novel Targets in the Immune Microenvironment of the Hepatic Sinusoids for Treating Liver Diseases
Patten, D. A., Shepherd, E. L., Weston, C. J., & Shetty, S. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1678727 · Cited by 11
Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice With High-Fat Diet-Induced Non-alcoholic Steatohepatitis
Yang, Y., Yu, L., Cheng, N., Liu, X., Fang, C., Liu, S., & Zhu, L. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.783341 · Cited by 11
A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease
Zhang, Q., Zhang, L., Liu, K., Shang, H., Ruan, J., Yu, Z., Meng, S., Liang, F., Wang, T., Zhang, H., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1638740 · Cited by 11
Exercise changes the intrahepatic immune cell profile and inhibits the progression of nonalcoholic steatohepatitis in a mouse model
Tsutsui, Y., Mori, T., Yoshio, S., Sato, M., Sakata, T., Yoshida, Y., Kawai, H., Yoshikawa, S., Yamazoe, T., Matsuda, M., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000236 · Cited by 10
Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis
Kholodenko, I. V., & Yarygin, K. N. (2023) · Biomedicines · doi:10.3390/biomedicines11113056 · Cited by 14
Hepatocytic Ballooning in Non-alcoholic Steatohepatitis: Bridging the Knowledge Gap and Charting Future Avenues
Singla, T., Muneshwar, K. N., Pathade, A. G., & Yelne, S. (2023) · Cureus · doi:10.7759/cureus.45884 · Cited by 10
Translational Control in Liver Disease
Balvey, A., & Fernández, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.795298 · Cited by 10
Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice
Lu, H., Ye, C., Feng, X., Liu, J., Bhaumik, M., Xia, B., Liu, C., & Shen, Z. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.020 · Cited by 10
The role of dendritic cells in MASH: friends or foes?
Pinto, A. T., & Lukacs‐Kornek, V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379225 · Cited by 10
Unlocking the potential: How acupuncture reshapes the liver-centered lipid metabolism pattern to fight obesity
Yang, S., Chen, L., Luo, D., Wang, Y.-Y., & Liang, F.-X. (2024) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2024.08.004 · Cited by 9
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
Feng, Q., Wu, M., & Mai, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1482918 · Cited by 12
Deficiency of CD147 Attenuated Non-alcoholic Steatohepatitis Progression in an NLRP3-Dependent Manner
Zhang, T., Li, H., Wang, K., Xu, B., Chen, Z., & Bian, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00784 · Cited by 9
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32479 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 8
Prognostic value of ALBI score for all-cause mortality in metabolic associated fatty liver disease patients: a cohort study from NHANES 2003–2018
Zhou, G., Han, W., Luan, J., & Ma, B. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04117-1 · Cited by 8
Rho-associated protein kinase 1 inhibition in hepatocytes attenuates nonalcoholic steatohepatitis
Dohnálková, E., Bayer, R. L., Guo, Q., Bamidele, A. O., Lee, H. S. K., Valenzuela-Pérez, L., Krishnan, A., Pavelko, K. D., Guisot, N. E. S., Bunyard, P., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000171 · Cited by 8
Self-citation
Nonalcoholic Steatohepatitis (NASH)
Mariño, G., Zeini, I. M., & Ghanem, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25828-2_8 · Cited by 8
Novel Mechanisms for Resolution of Liver Inflammation: Therapeutic Implications
Kaufmann, B. K., Reca, A., Kim, A. D., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723031 · Cited by 8
Histopathology of Nonalcoholic Fatty Liver Disease
TINIAKOS, D. G., & Sakellariou, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_3 · Cited by 8
Punicalagin relieves hepatic injury by antioxidation and enhancement of autophagy in diet-induced nonalcoholic steatohepatitis
Ma, L., Sun, H., Xiang, N., & Xu, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-98044-6 · Cited by 7
GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responses via PPARγ/STAT3 signaling pathways
Wang, Y., Zhang, X., Yuan, B., Lü, X., Zheng, D., Zhang, K., Zhong, M., Xu, X., & Duan, X. (2019) · RSC Advances · doi:10.1039/c8ra10178g · Cited by 7
Ephrin–Eph receptor tyrosine kinases for potential therapeutics against hepatic pathologies
Mekala, S., Dugam, P., & Das, A. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00750-1 · Cited by 7

Authors: Ibrahim, S. H., Hirsova, P., & Gores, G. J.
Affiliations: Mayo Clinic (US)
Charles University (CZ)
Corresponding author: Gores, Gregory J
ORCID: Ibrahim, Samar H
Hirsova, Petra
Gores, Gregory J
Venue: Gut
Publisher: BMJ
Published: 2018-01-24
Volume: 67
Issue: 5
Pages: 963-972
ISSN: 0017-5749 (ISSN-L)
1468-3288
DOI: 10.1136/gutjnl-2017-315691
PMC: PMC5889737
OpenAlex: W2784619339
Cited by: 278
References: 89
Citations by year: 2026: 20 · 2025: 26 · 2024: 28 · 2023: 29 · 2022: 37 · 2021: 50 · 2020: 43 · 2019: 28 · 2018: 17
FWCI: 4.93
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Gut (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
HighWire Press Open Archive (submittedVersion)
Funders: Mayo Clinic
Gilead Sciences
MH CZ–DRO
National Institute of Diabetes and Digestive and Kidney Diseases
North American Society of Pediatric Gastroenterology Hepatology and Nutrition Young Investigator Award/Nestle Nutrition Award
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, lipotoxicity, lipid overload, liver inflammation, liver fibrosis, disease biomarkers, treatment options
MeSH terms: Animals, Hepatitis, Humans, Lipids, Liver, Signal Transduction, Hepatocytes, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks